Daiichi Sankyo develops and markets pharmaceuticals. The Company offers therapies in the areas of hypertension, dyslipidemia, diabetes, acute coronary syndrome, metastatic melanoma, cardiology, oncology, pain, and other aspects. It serves customers in the United States and internationally.

TypePublic
HQParsippany-Troy Hills, US
Size (employees)3,168 (est)
Websitedaiichisankyo.com
Daiichi Sankyo is headquartered in Parsippany-Troy Hills, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Daiichi Sankyo

George Nakayama

George Nakayama

Representative Director, Chairman and CEO
Sunao Manabe

Sunao Manabe

Representative Director, Member of the Board, President and COO
Toshiaki Sai

Toshiaki Sai

Representative Director, Member of the Board, Executive Vice President and CFO
Katsumi Fujimoto

Katsumi Fujimoto

Member of the Board, Senior Executive Officer
Noritaka Uji

Noritaka Uji

Member of the Board (Outside)
Hideyuki Haruyama

Hideyuki Haruyama

Member of the Audit and Supervisory Board
Show more

Daiichi Sankyo Office Locations

Daiichi Sankyo has an office in Parsippany-Troy Hills
Parsippany-Troy Hills, US (HQ)
2 Hilton Ct
Show all (1)
Report incorrect company information

Daiichi Sankyo Online and Social Media Presence

Embed Graph
Report incorrect company information

Daiichi Sankyo News and Updates

Shivinder Singh offers Delhi HC to allow him to mediate with Daiichi Sankyo

The Delhi high court has directed him to come up with a ‘proposal’ to pay his share out of the arbitral award of ₹ 3,500 crore by 30 October, the next date of hearing in the Daiichi Sankyo case

Daiichi Sankyo Initiates Two Phase 3 Trials of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Positive Metastatic Breast Cancer including Head-to-Head Versus T-DM1 and Post-T-DM1 Study

TOKYO, MUNICH, and BASKING RIDGE, N.J., Sept. 25, 2018 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patients have been dosed in DESTINY-Breast03 and DESTINY-Breast02, two global phase 3 studies evaluating the safety and efficacy of...

Daiichi Sankyo Presents Updated Results for [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Mutated or HER2 Expressing Non-Small Cell Lung Cancer at IASLC 19th World Conference on Lung Cancer

TOKYO, MUNICH, and BASKING RIDGE, N.J., Sept. 24, 2018 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that updated phase 1 safety and efficacy data for [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate ...

Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-8201 in Combination with KEYTRUDA® (pembrolizumab) in HER2 Expressing Breast and HER2 Expressing or HER2 Mutant Lung Cancers

TOKYO and BASKING RIDGE, N.J., Sept. 20, 2018 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration agreement with a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A., known as MSD...

Daiichi Sankyo Moves NCLT To Stay Insolvency Plea Against RHC Holding

With the Daiichi-RHC matter listed for Oct. 4, the NCLT has asked RHC Holding. its lender HDFC Bank to file a reply within a week.

Daiichi Sankyo moves NCLT to stay RHC Holdings proceedings

A two-member NCLT bench has asked RHC Holdings and HDFC Bank to file a reply over Daiichi Sankyo’s move within a week
Show more
Report incorrect company information

Daiichi Sankyo Company Life and Culture

Report incorrect company information